Scandinavian ChemoTech

We are delighted to extend an invitation to you for an insightful presentation hosted by Scandinavian ChemoTech featuring distinguished speakers: MD Suhail Mufti, CEO Mohan Frick, and Chairman of the Board Robin Sukhia. The event will take place on Monday, January 29th, and will focus on the recent approval of the amended study protocol for Head & Neck cancer and its implications for our clinical strategy, as well as the potential impact on our commercial opportunities.

Additionally, there will be an interactive opportunity for attendees to ask questions and gain further clarity on the presented topics.

Event Details:

Date: Monday, January 29th, 2024

Time: 12:00 - 12:45

Location: ZOOM

Join Zoom Meeting:

https://us06web.zoom.us/j/87201327011?pwd=RTR7FoSo6KxyameCSQea1yzQCTcuM2.1

Meeting ID: 872 0132 7011

Passcode: 005706

Why Attend?

• Gain valuable insights into ChemoTech.
• Understand the strategic implications of the recent approval.
• Explore potential opportunities and challenges in the commercial space.

We look forward to your participation in this important event as we navigate the evolving landscape of TSEs future endeavors.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.